OA11464A - Combination of active principles, in particular oftetrahydropyridins and acetylcholinesterase inhib iting agents, for treating senile dementia such asAlzheimer dementia. - Google Patents

Combination of active principles, in particular oftetrahydropyridins and acetylcholinesterase inhib iting agents, for treating senile dementia such asAlzheimer dementia. Download PDF

Info

Publication number
OA11464A
OA11464A OA1200000141A OA1200000141A OA11464A OA 11464 A OA11464 A OA 11464A OA 1200000141 A OA1200000141 A OA 1200000141A OA 1200000141 A OA1200000141 A OA 1200000141A OA 11464 A OA11464 A OA 11464A
Authority
OA
OAPI
Prior art keywords
tetrahydropyridine
ethyl
trifluoromethylphenyl
biphenylyl
alkyl
Prior art date
Application number
OA1200000141A
Other languages
English (en)
Inventor
Jean-Pierre Maffrand
Philippe Soubrie
Jean-Paul Terranova
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9714324A external-priority patent/FR2771006B1/fr
Priority claimed from FR9714322A external-priority patent/FR2771007B1/fr
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of OA11464A publication Critical patent/OA11464A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
OA1200000141A 1997-11-14 2000-05-12 Combination of active principles, in particular oftetrahydropyridins and acetylcholinesterase inhib iting agents, for treating senile dementia such asAlzheimer dementia. OA11464A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9714324A FR2771006B1 (fr) 1997-11-14 1997-11-14 Association de principes actifs pour le traitement de la demence senile du type alzheimer
FR9714322A FR2771007B1 (fr) 1997-11-14 1997-11-14 Association de principes actifs pour le traitement de la demence senile du type alzheimer

Publications (1)

Publication Number Publication Date
OA11464A true OA11464A (en) 2003-11-18

Family

ID=26233932

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200000141A OA11464A (en) 1997-11-14 2000-05-12 Combination of active principles, in particular oftetrahydropyridins and acetylcholinesterase inhib iting agents, for treating senile dementia such asAlzheimer dementia.

Country Status (27)

Country Link
EP (1) EP1030671A1 (pl)
JP (1) JP2001523642A (pl)
KR (1) KR100599350B1 (pl)
CN (1) CN1243540C (pl)
AU (1) AU743228B2 (pl)
BG (1) BG64819B1 (pl)
BR (1) BR9814035A (pl)
CA (1) CA2309966A1 (pl)
CO (1) CO4980891A1 (pl)
DZ (1) DZ2649A1 (pl)
EA (1) EA003255B1 (pl)
EE (1) EE04235B1 (pl)
HU (1) HUP0100098A3 (pl)
ID (1) ID24933A (pl)
IL (2) IL136122A0 (pl)
IS (1) IS5482A (pl)
MY (1) MY120461A (pl)
NO (1) NO20002450L (pl)
NZ (1) NZ504420A (pl)
OA (1) OA11464A (pl)
PL (1) PL194597B1 (pl)
SA (1) SA98190747B1 (pl)
SK (1) SK286040B6 (pl)
TR (1) TR200001262T2 (pl)
TW (1) TW585766B (pl)
UY (1) UY25247A1 (pl)
WO (1) WO1999025363A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE42327E1 (en) 2002-06-14 2011-05-03 Toyama Chemical Co., Ltd. Medicinal compositions improving brain function and method for improving brain function
DK1529116T3 (da) * 2002-08-07 2009-11-09 Novartis Ag Fremgangsmåde til forudsigelse af respons på behandling med rivastigmin baseret på ApoE-genotypen hos demenspatienter
CN1520818A (zh) * 2003-02-09 2004-08-18 山东绿叶天然药物研究开发有限公司 治疗老年性痴呆的胆碱酯酶抑制剂药物组合物
AU2005320547B2 (en) 2004-12-27 2009-02-05 Eisai R & D Management Co., Ltd. Method for stabilizing anti-dementia drug
DK3099296T3 (en) 2014-01-31 2019-04-15 Cognition Therapeutics Inc ISO-INDOLINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE
IL270251B2 (en) * 2017-05-15 2025-01-01 Cognition Therapeutics Inc 1-Phenyl-1,1-dimethyl-2-(piperidinyl/pyrrolidinyl/piperazinyl)ethane derivatives and pharmaceutical preparations containing them
KR102224917B1 (ko) 2018-03-20 2021-03-09 (주)인벤티지랩 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물의 제조 방법 및 이의 제조 방법으로 제조된 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물
WO2019182319A1 (ko) * 2018-03-20 2019-09-26 (주)인벤티지랩 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물의 제조 방법 및 이의 제조 방법으로 제조된 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물
CN109265391B (zh) * 2018-11-13 2021-11-19 枣庄学院 联苯多取代1,2,5,6-四氢吡啶化合物及其合成方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
US5453428A (en) * 1991-02-14 1995-09-26 The Mount Sinai School Of Medicine Of The City Of New York Method and composition for the treatment of apathy-amotivation syndrome
EP0813416B1 (en) * 1995-03-06 2005-05-25 Interneuron Pharmaceuticals Incorporated Reduction of infarct volume using citicoline
FR2736053B1 (fr) * 1995-06-28 1997-09-19 Sanofi Sa Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines

Also Published As

Publication number Publication date
JP2001523642A (ja) 2001-11-27
PL340500A1 (en) 2001-02-12
ID24933A (id) 2000-08-31
EP1030671A1 (fr) 2000-08-30
DZ2649A1 (fr) 2004-12-28
NO20002450L (no) 2000-07-14
PL194597B1 (pl) 2007-06-29
EA200000412A1 (ru) 2000-12-25
CA2309966A1 (en) 1999-05-27
CN1285742A (zh) 2001-02-28
HUP0100098A3 (en) 2001-12-28
EA003255B1 (ru) 2003-02-27
SK7112000A3 (en) 2000-10-09
KR20010032099A (ko) 2001-04-16
EE200000290A (et) 2001-06-15
CN1243540C (zh) 2006-03-01
CO4980891A1 (es) 2000-11-27
KR100599350B1 (ko) 2006-07-12
IL136122A0 (en) 2001-05-20
BG104428A (en) 2001-08-31
BG64819B1 (bg) 2006-05-31
IL136122A (en) 2006-07-05
IS5482A (is) 2000-05-09
AU743228B2 (en) 2002-01-24
SK286040B6 (sk) 2008-01-07
HUP0100098A2 (hu) 2001-07-30
UY25247A1 (es) 2001-05-31
NZ504420A (en) 2003-08-29
SA98190747B1 (ar) 2006-11-04
WO1999025363A1 (fr) 1999-05-27
TW585766B (en) 2004-05-01
EE04235B1 (et) 2004-02-16
BR9814035A (pt) 2000-09-26
MY120461A (en) 2005-10-31
NO20002450D0 (no) 2000-05-11
AU1160999A (en) 1999-06-07
TR200001262T2 (tr) 2001-01-22

Similar Documents

Publication Publication Date Title
CA2282654C (en) Use of cholinesterase inhibitors to treat attention deficit hyperactivity disorder
EP0216555B1 (en) Use of dioxopiperidine derivatives in the treatment of anxiety, for the reduction of chronic abnormally high brain levels of serotonin or 5-hydroxy-indoleacetic acid, and in the treatment of bacterial or viral infections
JPH08225464A (ja) 嘔吐治療用ｎｋ−１受容体アンタゴニスト及び５ｈｔ３受容体アンタゴニスト
EP0279114B1 (en) Medicaments for the treatment or prevention of the withdrawal syndrome
NZ547152A (en) Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor
CA2323618A1 (en) Combination of a gaba-a alpha 5 inverse agonist and an acetylcholinesterase inhibitor
OA11464A (en) Combination of active principles, in particular oftetrahydropyridins and acetylcholinesterase inhib iting agents, for treating senile dementia such asAlzheimer dementia.
Stewart et al. The pharmacological characterisation of pilocarpine-induced purposeless chewing behaviour in the rat
US20030092737A1 (en) Combination of active ingredients for the treatment of senile dementia of the Alzheimer type
US4479956A (en) Analgesic compositions comprising propiram and methods of using same
MXPA00004600A (en) Combination of active principles, in particular of tetrahydropyridins and acetylcholinesterase inhibiting agents, for treating senile dementia such as alzheimer dementia
CZ20001734A3 (cs) Farmaceutická kompozice a její použití
CA2188227C (en) Combination antiemetic therapy using nk-1 receptor antagonists
US5852044A (en) Use of NK1 receptor antagonists for preparing cardio-regulatory drugs
DE3736505A1 (de) Kombination von clacium antagonisten mit einem ace-hemmer
TH65396C3 (th) องค์ประกอบสำหรับให้ทางปากของ 8-คลอโร-6, 11-ไดไฮโดร-11-(4-ปิปเปอริดิลลิดีน)-5H-เบนโซ[5,6] ไซโคลเฮปตา[1,2-b] ไพริดีน
TH48162A3 (th) องค์ประกอบสำหรับให้ทางปากของ 8-คลอโร-6, 11-ไดไฮโดร-11-(4-ปิปเปอริดิลลิดีน)-5H-เบนโซ[5,6] ไซโคลเฮปตา[1,2-b] ไพริดีน
FR2771007A1 (fr) Association de principes actifs pour le traitement de la demence senile du type alzheimer
JPWO2001022997A1 (ja) 鎮痛薬
SI21062A2 (sl) Farmacevtski sestavki, ki obsegajo amlodipin maleat